815 reports of this reaction
1.8% of all PIPERACILLIN SODIUM,TAZOBACTAM SODIUM reports
#11 most reported adverse reaction
FEBRILE NEUTROPENIA is the #11 most commonly reported adverse reaction for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 815 FDA adverse event reports linking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM to FEBRILE NEUTROPENIA. This represents approximately 1.8% of all 44,977 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 815 FDA reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 1.8% of all adverse event reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, making it a notable side effect.
If you experience febrile neutropenia while taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.